News
Wednesday, October 23rd, 2013
The Lancet Diabetes & Endocrinology, Early Online Publication, October 18, 2013 Type 2 diabetes is associated with dementia, and also with more slight cognitive decrements. In this Review we discuss trajectories from normal cognition to dementia in people with type 2 diabetes, and explore opportunities for treatment. Slight diabetes-associated cognitive decrements and dementia affect […]
News
Wednesday, October 23rd, 2013
Future Medicine: November 2013 SUMMARY The incidence of diabetes is increasing globally, resulting in an ever-increasing social and economic burden. Despite advances in treatment options, metabolic control often remains suboptimal, resulting in high levels of morbidity and mortality, and increased healthcare expenditure. Current guidelines advocate individualized treatment and a multidisciplinary approach to disease management. For these recommendations […]
News
Wednesday, October 23rd, 2013
Future Medicine: November 2013 SUMMARY Diabetic retinopathy (DR) is the leading cause of new-onset blindness in working-age individuals in the USA and represents a growing worldwide epidemic. Classic risk factors for onset or progression of DR include poor glycemic control, hypertension and hyperlipidemia; however, these factors account for only a small proportion of the risk of DR. […]
News
Wednesday, October 23rd, 2013
Diabetes Care October 15, 2013 Objective To evaluate the risk of complications in youth with type 2 diabetes. Research Design and Methods Population based cohorts of 342 prevalent youth (1-18 yrs) with type 2 diabetes, 1011 youth with type 1 diabetes and 1710 non-diabetes controls identified between 1986-2007 from a clinical registry and were linked to healthcare records […]
News
Wednesday, October 23rd, 2013
The Lancet: October 88, 2013 Background The comparative performance of existing models for prediction of type 2 diabetes across populations has not been investigated. We validated existing non-laboratory-based models and assessed variability in predictive performance in European populations. Methods We selected non-invasive prediction models for incident diabetes developed in populations of European ancestry and validated […]
Minority Diabetes Reports
Monday, October 21st, 2013
BMC: October 11, 2013 Several studies in type 2 diabetes patients have shown significant associations between the SOD2 gene Val16Ala polymorphism and albuminuria, but this association has not been explored in the Mexican population. Methods We evaluated the association between the SOD2 gene Val16Ala polymorphism (rs4880) and macroalbuminuria in a sample of 994 unrelated Mexican […]
News
Monday, October 21st, 2013
Ann Intern Med.: 10/15/13 Background: The effect of multifaceted lifestyle interventions on clinically oriented outcomes across a spectrum of metabolic risk factors and abnormal glucose is unclear. Purpose: To systematically review the effectiveness of lifestyle interventions on minimizing progression to diabetes in high-risk patients or progression to clinical outcomes (such as cardiovascular disease and death) in patients with […]
Minority Diabetes Reports
Thursday, October 17th, 2013
CNN: October 17, 2013 Editor’s note: This story is part three in a three-part series about health issues in the Latino community in honor of Hispanic Heritage Month. Read CNN’s other stories about the stigma that affects Latinos with mental health, and the “Hispanic Paradox” that exists for those fighting cancer. (CNN) — Elma Dieppa wonders if her cousin […]
Clinical Trial News
Thursday, October 17th, 2013
Am J Clin Nutr: October 16, 2013 Background: To our knowledge, there is no study that has examined the effects of vitamin D supplementation on metabolic status in gestational diabetes mellitus (GDM). Objective: This study was designed to assess the effects of vitamin D supplementation on metabolic profiles, high-sensitivity C-reactive protein, and biomarkers of oxidative stress in […]
Clinical Trial News
Thursday, October 17th, 2013
Diabetes Care: October 8, 2013 Objective To evaluate over 108 weeks the effect of phentermine and topiramate extended-release (PHEN/TPM ER) treatment on progression to type 2 diabetes and/or cardiometabolic disease in subjects with Prediabetes and/or Metabolic Syndrome (MetS) at baseline. Research Design and Methods Subanalysis of a Phase 3, randomized, placebo-controlled, double-blind study of overweight/obese subjects (BMI ≥27 […]
